Cargando…

Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus

OBJECTIVES: Type I interferons (IFNs) are central and reflective of disease activity in systemic lupus erythematosus (SLE). However, IFN-α levels are notoriously difficult to measure and the type I IFN gene signature (IGS) is not yet available in clinical routine. This study evaluates galectin-9 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Enocsson, Helena, Wetterö, Jonas, Eloranta, Maija-Leena, Gullstrand, Birgitta, Svanberg, Cecilia, Larsson, Marie, Bengtsson, Anders A., Rönnblom, Lars, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278235/
https://www.ncbi.nlm.nih.gov/pubmed/34276678
http://dx.doi.org/10.3389/fimmu.2021.688753
_version_ 1783722226452791296
author Enocsson, Helena
Wetterö, Jonas
Eloranta, Maija-Leena
Gullstrand, Birgitta
Svanberg, Cecilia
Larsson, Marie
Bengtsson, Anders A.
Rönnblom, Lars
Sjöwall, Christopher
author_facet Enocsson, Helena
Wetterö, Jonas
Eloranta, Maija-Leena
Gullstrand, Birgitta
Svanberg, Cecilia
Larsson, Marie
Bengtsson, Anders A.
Rönnblom, Lars
Sjöwall, Christopher
author_sort Enocsson, Helena
collection PubMed
description OBJECTIVES: Type I interferons (IFNs) are central and reflective of disease activity in systemic lupus erythematosus (SLE). However, IFN-α levels are notoriously difficult to measure and the type I IFN gene signature (IGS) is not yet available in clinical routine. This study evaluates galectin-9 and an array of chemokines/cytokines in their potential as surrogate markers of type I IFN and/or SLE disease activity. METHODS: Healthy controls and well-characterized Swedish SLE patients from two cross-sectional cohorts (n=181; n=59) were included, and a subgroup (n=21) was longitudinally followed. Chemokine/cytokine responses in immune complex triggered IFN-α activity was studied in healthy donor peripheral blood mononuclear cells (PBMC). Levels of chemokines/cytokines and galectin-9 were measured by immunoassays. Gene expression was quantified by qPCR. RESULTS: The IGS was significantly (p<0.01) correlated with galectin-9 (rho=0.54) and CXCL10 (rho=0.37) levels whereas serum IFN-α correlated with galectin-9 (rho=0.36), CXCL10 (rho=0.39), CCL19 (rho=0.26) and CCL2 (rho=0.19). The strongest correlation was observed between galectin-9 and TNF (rho=0.56). IFN-α and disease activity (SLEDAI-2K) were correlated (rho=0.20) at cross-sectional analysis, but no significant associations were found between SLEDAI-2K and galectin-9 or chemokines. Several inflammatory mediators increased at disease exacerbation although CCL19, CXCL11, CXCL10, IL-10 and IL-1 receptor antagonist were most pronounced. Immune complex-stimulation of PBMC increased the production of CCL2, CXCL8 and TNF. CONCLUSION: Galectin-9 and CXCL10 were associated with type I IFN in SLE but correlated stronger with TNF. None of the investigated biomarkers showed a convincing association with disease activity, although CXCL10 and CCL19 performed best in this regard.
format Online
Article
Text
id pubmed-8278235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82782352021-07-15 Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus Enocsson, Helena Wetterö, Jonas Eloranta, Maija-Leena Gullstrand, Birgitta Svanberg, Cecilia Larsson, Marie Bengtsson, Anders A. Rönnblom, Lars Sjöwall, Christopher Front Immunol Immunology OBJECTIVES: Type I interferons (IFNs) are central and reflective of disease activity in systemic lupus erythematosus (SLE). However, IFN-α levels are notoriously difficult to measure and the type I IFN gene signature (IGS) is not yet available in clinical routine. This study evaluates galectin-9 and an array of chemokines/cytokines in their potential as surrogate markers of type I IFN and/or SLE disease activity. METHODS: Healthy controls and well-characterized Swedish SLE patients from two cross-sectional cohorts (n=181; n=59) were included, and a subgroup (n=21) was longitudinally followed. Chemokine/cytokine responses in immune complex triggered IFN-α activity was studied in healthy donor peripheral blood mononuclear cells (PBMC). Levels of chemokines/cytokines and galectin-9 were measured by immunoassays. Gene expression was quantified by qPCR. RESULTS: The IGS was significantly (p<0.01) correlated with galectin-9 (rho=0.54) and CXCL10 (rho=0.37) levels whereas serum IFN-α correlated with galectin-9 (rho=0.36), CXCL10 (rho=0.39), CCL19 (rho=0.26) and CCL2 (rho=0.19). The strongest correlation was observed between galectin-9 and TNF (rho=0.56). IFN-α and disease activity (SLEDAI-2K) were correlated (rho=0.20) at cross-sectional analysis, but no significant associations were found between SLEDAI-2K and galectin-9 or chemokines. Several inflammatory mediators increased at disease exacerbation although CCL19, CXCL11, CXCL10, IL-10 and IL-1 receptor antagonist were most pronounced. Immune complex-stimulation of PBMC increased the production of CCL2, CXCL8 and TNF. CONCLUSION: Galectin-9 and CXCL10 were associated with type I IFN in SLE but correlated stronger with TNF. None of the investigated biomarkers showed a convincing association with disease activity, although CXCL10 and CCL19 performed best in this regard. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8278235/ /pubmed/34276678 http://dx.doi.org/10.3389/fimmu.2021.688753 Text en Copyright © 2021 Enocsson, Wetterö, Eloranta, Gullstrand, Svanberg, Larsson, Bengtsson, Rönnblom and Sjöwall https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Enocsson, Helena
Wetterö, Jonas
Eloranta, Maija-Leena
Gullstrand, Birgitta
Svanberg, Cecilia
Larsson, Marie
Bengtsson, Anders A.
Rönnblom, Lars
Sjöwall, Christopher
Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title_full Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title_fullStr Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title_full_unstemmed Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title_short Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
title_sort comparison of surrogate markers of the type i interferon response and their ability to mirror disease activity in systemic lupus erythematosus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278235/
https://www.ncbi.nlm.nih.gov/pubmed/34276678
http://dx.doi.org/10.3389/fimmu.2021.688753
work_keys_str_mv AT enocssonhelena comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT wetterojonas comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT elorantamaijaleena comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT gullstrandbirgitta comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT svanbergcecilia comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT larssonmarie comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT bengtssonandersa comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT ronnblomlars comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus
AT sjowallchristopher comparisonofsurrogatemarkersofthetypeiinterferonresponseandtheirabilitytomirrordiseaseactivityinsystemiclupuserythematosus